LS Investment Advisors LLC acquired a new position in Xencor Inc (NASDAQ:XNCR) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,048 shares of the biopharmaceutical company’s stock, valued at approximately $170,000.
Several other institutional investors have also recently modified their holdings of XNCR. Marshall Wace LLP raised its position in shares of Xencor by 1,320.1% in the second quarter. Marshall Wace LLP now owns 364,291 shares of the biopharmaceutical company’s stock worth $14,910,000 after acquiring an additional 338,639 shares during the period. EcoR1 Capital LLC increased its stake in shares of Xencor by 13.5% during the second quarter. EcoR1 Capital LLC now owns 2,336,557 shares of the biopharmaceutical company’s stock worth $95,635,000 after purchasing an additional 277,128 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Xencor during the second quarter worth about $11,073,000. BlackRock Inc. increased its stake in shares of Xencor by 5.2% during the second quarter. BlackRock Inc. now owns 4,324,181 shares of the biopharmaceutical company’s stock worth $176,988,000 after purchasing an additional 213,329 shares in the last quarter. Finally, Marshall Wace North America L.P. increased its stake in shares of Xencor by 35,376.8% during the second quarter. Marshall Wace North America L.P. now owns 155,743 shares of the biopharmaceutical company’s stock worth $6,375,000 after purchasing an additional 155,304 shares in the last quarter. Institutional investors and hedge funds own 84.42% of the company’s stock.
In other Xencor news, VP John R. Desjarlais sold 35,000 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $40.69, for a total value of $1,424,150.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John J. Kuch sold 40,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $41.27, for a total transaction of $1,650,800.00. The disclosure for this sale can be found here. Corporate insiders own 4.33% of the company’s stock.
Shares of NASDAQ XNCR opened at $33.26 on Friday. The stock has a market cap of $1.87 billion, a PE ratio of -25.39 and a beta of 1.34. Xencor Inc has a 12-month low of $27.75 and a 12-month high of $46.33. The company has a current ratio of 8.27, a quick ratio of 8.27 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $35.01 and a 200 day moving average of $36.58.
Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.40. Xencor had a net margin of 21.60% and a return on equity of 5.92%. The company had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. On average, sell-side analysts forecast that Xencor Inc will post 0.05 EPS for the current fiscal year.
A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a research note on Saturday, October 5th. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Thursday. Guggenheim cut shares of Xencor from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Wedbush boosted their target price on shares of Xencor from $43.00 to $54.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. They noted that the move was a valuation call. Finally, Leerink Swann cut their target price on shares of Xencor from $52.00 to $44.00 and set an “outperform” rating for the company in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $43.90.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: Catch-Up Contributions
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.